Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Summary

This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease).

Timeline

Start

2024-09-13

Primary completion

2025-12-31

Completion

2025-12-31

Outcome

Outcome not reported

Stopped: “Unable to identify patients who meet eligibility requirements of tissue needed for analysis.”

Drugs

Indications